Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $8.29.
Several research firms have recently commented on VTYX. HC Wainwright reissued a "neutral" rating and set a $6.00 price target on shares of Ventyx Biosciences in a research note on Monday, September 23rd. Wells Fargo & Company reduced their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating on the stock in a research note on Monday, August 12th. Canaccord Genuity Group reduced their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. Finally, Oppenheimer reduced their price objective on shares of Ventyx Biosciences from $12.00 to $10.00 and set an "outperform" rating on the stock in a research note on Thursday, June 6th.
Check Out Our Latest Report on VTYX
VTYX opened at $2.11 on Thursday. Ventyx Biosciences has a one year low of $1.79 and a one year high of $31.01. The company's 50 day simple moving average is $2.21 and its 200-day simple moving average is $3.44. The stock has a market capitalization of $149.11 million, a P/E ratio of -0.65 and a beta of 0.37.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.12. As a group, analysts anticipate that Ventyx Biosciences will post -2.14 EPS for the current year.
A number of hedge funds have recently modified their holdings of VTYX. SG Americas Securities LLC acquired a new stake in shares of Ventyx Biosciences during the second quarter worth about $32,000. The Manufacturers Life Insurance Company raised its position in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock worth $56,000 after purchasing an additional 7,096 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ventyx Biosciences during the second quarter worth about $58,000. Norden Group LLC acquired a new stake in shares of Ventyx Biosciences during the first quarter worth about $59,000. Finally, American Century Companies Inc. acquired a new stake in shares of Ventyx Biosciences during the second quarter worth about $60,000. Institutional investors and hedge funds own 97.88% of the company's stock.
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.